The deal will see the companies provide a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, especially in the context of regulatory studies.
Under the deal, Harlan CRS will strengthen its drug discovery and translational medicine offerings using Bertin Pharma’s expertise in immunology and biomarkers.
Harlan CRS president Manuela Leone said, "We welcome this strategic agreement with Bertin Pharma. Its expertise in the immunological sector is impressive and well-known in the industry."
Harlan CRS director of strategic initiatives and director of drug discovery and translational medicine Ciriaco Maraschiello said the new agreement benefits the company both strategically and scientifically.
"Working together, we will provide the pharmaceutical industry the best team of scientists to increase the likelihood of success for new generation drugs," Maraschiello said.
Bertin Pharma managing director Xavier Morge said, "For Bertin Pharma, this partnership will increase our international visibility and allow us to expand our services by integrating project management capabilities and expertise."